Targeting menin for precision therapy in high-risk acute myeloid leukemia.

Objective: This mini-review provides an overview of the current evidence for Revumenib, a first-in-class menin inhibitor, in treating AML with KMT2A rearrangements or NPM1 mutations. This therapy represents a promising advancement by selectively disrupting leukemogenic pathways.

Summary: The clinical promise of Revumenib in genetically defined AML highlights its potential role in shaping the future treatment landscape.

Unlocking the Photoluminescence and Photostability of Au Clusters through Pt-Mediated Band-Gap Engineering.

Au nanoclusters often demonstrate useful optical properties such as visible/near-infrared photoluminescence, in addition to remarkable thermodynamic stability owing to their superatomic behavior. The smallest of the 8e superatomic Au nanoclusters, Au, has limited applications due to its lack of luminescence and relatively low stability. In this work, we investigate the introduction of a single Pt dopant to the center of a halide- and triphenylphosphine-ligated Au nanocluster, affording a cluster with a proposed molecular formula PtAu(PPh)Br.

Talazoparib for the Treatment of Metastatic Castration-resistant Prostate Cancer: A Narrative Review.

Breast and prostate cancer are among the most commonly diagnosed cancers worldwide. Recent advances in tumor sequencing and gene studies have led to a paradigm shift from treatment centered on the type of tumor to therapy more focused on specific immune phenotype markers and molecular alterations. In this review, we discuss the utility and function of talazoparib concerning prostate cancer treatment and summarize recent and planned clinical trials on talazoparib.

Efficacy and Safety of Probiotics as Adjunctive Therapy in Cancer Treatment: A Comprehensive Systematic Review and Meta-Analysis.

Objectives: The gut microbiome is crucial in influencing cancer progression and response to treatment. We evaluate the efficacy and safety of probiotics and synbiotics in cancer treatment, focusing on the incidence of diarrhea, significant complications, surgical site infections, length of hospital stay, progression-free survival (PFS), and overall survival (OS).

Methods: Following PRISMA guidelines, a comprehensive literature search was conducted in PubMed, Scopus, Web of Science, and Cochrane CENTRAL up to June 2024.

Advancements in breast cancer management: a comprehensive review of ribociclib combined with endocrine therapy.

Background: In this review, the complicated landscape of breast cancer management is explored with a focus on the promising synergies between ribociclib and endocrine therapy. Ribociclib mainly acts as a cyclin-dependent kinase 4/6 (CDK4/6) inhibitor, which disrupts cell cycle progression necessary for tumor growth. This, in combination with endocrine therapy, aims to produce hormone receptor-positive breast cancers, which is a very relevant subtype with challenging therapeutics.